#Acclaro Medical #2910 nm Laser #Accelmed Partners

Acclaro Medical's Remarkable Journey and New Funding

Acclaro Medical has recently announced a significant milestone in its journey within the medical technology sector. The Rhode Island-based company has successfully completed its Series B funding round, raising a total of $23 million. This round was led by Accelmed Partners, with crucial participation from existing investor 3E Bioventures Capital. The funding signifies a substantial leap forward for Acclaro, aimed at fulfilling unmet needs in aesthetic medicine through its advanced 2910 nm fiber laser solution and other innovative technologies.

The Groundbreaking 2910 nm Fiber Laser Technology

At the heart of Acclaro Medical’s offerings is its UltraClear fiber laser, a device that has been heralded by industry professionals as a groundbreaking solution in Total Skin Health. This laser not only addresses multiple skin layers but also plays a vital role in reversing the visible signs of aging, all while ensuring safety across diverse patient demographics, including those with varied skin types. Equipped with proprietary 3DIntelliPulse™ technology, the UltraClear laser delivers superior clinical outcomes and facilitates a treatment experience that minimizes patient discomfort and downtime.

The aesthetic industry has long sought a versatile and safe laser solution for treating various skin conditions. Acclaro’s innovative technology promises to transform how practitioners address skin health, emphasizing safety, efficacy, and patient satisfaction.

A Vision for the Future